Is BNTX a good stock to buy? We came across a bullish thesis on BioNTech SE on r/ValueInvesting by birdflustocks. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $86.50 as of June 9th. BNTX’s trailing and forward P/E were 166.87 and 7.04 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
BioNTech (BNTX) is a German biotechnology company whose market capitalization of roughly 21 billion USD is nearly matched by about 20 billion USD in cash, cash equivalents and securities, implying the operating business is being valued close to zero despite a strong underlying asset base. Post-COVID normalization has pressured sentiment as vaccine revenues decline, leading investors to mischaracterize BioNTech either as a cash-burning biotech or as a mature pharma company, overlooking its substantial balance sheet strength and long-term R&D-driven reinvestment strategy.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company invests about 2.5 billion USD annually in R&D against roughly 3 billion USD revenue trending toward 2.5 billion USD, with net losses of 0.8 billion USD in 2024 and 1.3 billion USD in 2025 reflecting pipeline expansion. Strategic optionality is supported by a Bristol Myers Squibb collaboration providing 1.5 billion USD upfront and 2 billion USD in non-contingent payments through 2028, alongside milestone upside and 50/50 profit sharing that de-risks oncology development. Despite founder departures and near-term earnings pressure, BioNTech maintains a broad pipeline across oncology and infectious diseases including influenza, HIV, malaria, tuberculosis, avian influenza and mpox.
The market underappreciates its intellectual property portfolio and late-stage assets, with expectations for multiple launches by 2030, seven oncology readouts in 2026, and around 15 Phase 3 trials supported by partners including Pfizer, Genentech and Regeneron. Overall, BioNTech is a mispriced opportunity where cash provides downside protection while pipeline optionality and upcoming clinical catalysts could drive a significant rerating toward long-term innovation value for long-term fundamental investors today view.
Previously, we covered a bullish thesis on Moderna, Inc. (MRNA) by YouAlwaysHaveAChoice in February 2025, which highlighted catalyst-driven upside from infectious disease risks, institutional positioning, and technical momentum. MRNA’s stock price has appreciated by approximately 43.41% since our coverage. birdflustocks shares a similar view but emphasizes BioNTech’s cash-backed valuation and pipeline optionality rather than short-term catalyst trading dynamics in a structurally different setup within biotech sector.
BioNTech SE is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held BNTX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the risk and potential of BNTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BNTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
